Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy.
Abstract
Adjuvant chemotherapy in patients with resected esophageal squamous cell cancer (ESCC)
remains controversial for its uncertain role in improving overall survival (OS). Nucleotide
excision repair (NER) removes DNA-adducts in tumor cells induced by the platinum-based
chemotherapy and thus may modulate efficacy of the treatment. The present study evaluated
if single nucleotide polymorphisms (SNPs) of NER genes were prognostic biomarkers
in ESCC patients treated with platinum-based adjuvant chemotherapy (PAC).The analysis
included 572 patients, for whom six SNPs of NER genes [i.e., XPC (rs1870134 and rs2228001),
ERCC2/XPD rs238406 and ERCC5/XPG (rs2094258, rs2296147 and rs873601)] were detected
with the TaqMan assay. Kaplan-Meier analyses and Cox proportional hazards models were
used to evaluate their associations with disease free survival (DFS) and OS of these
ESCC patients receiving PAC. Receiving operating characteristic curve analysis was
used to evaluate the role of the risk genotypes in the DFS and OS.We found that ERCC5/XPG
rs2094258 and rs873601 and ERCC2/XPD rs238406 SNPs were independently associated with
poorer DFS and OS of ESCC patients [ERCC5/XPG rs2094258: CT+TT vs. CC: adjusted hazards
ratio (adjHR) = 1.68 and P = 0.012 for DFS; adjHR = 1.99 and P = 0.0001 for OS; ERCC5/XPG
rs873601: GA+GG vs. AA: adjHR = 1.59 and P = 0.024 for DFS; adjHR = 1.91 and P = 0.0005
for OS; ERCC2/XPD rs238406: TT vs. GG+GT: adjHR = 1.43 and P = 0.020 for DFS; adjHR = 1.52
and P = 0.008 for OS]. These HRs increased as the number of risk genotypes increased
in the combined analysis. The model combining the risk genotypes with clinical characteristics
or the TNM stage system was better in predicting outcomes in ESCC patients with PAC.SNPs
of ERCC2/XPD and ERCC5/XPG may independently and jointly predict survival of ESCC
patients treated with PAC in this study population. Further validation in other study
populations is warranted.
Type
Journal articleSubject
HumansCarcinoma, Squamous Cell
Esophageal Neoplasms
Platinum
Prognosis
Disease-Free Survival
Chemotherapy, Adjuvant
Multivariate Analysis
ROC Curve
Demography
DNA Repair
Polymorphism, Single Nucleotide
Asian Continental Ancestry Group
Genetic Association Studies
Kaplan-Meier Estimate
Permalink
https://hdl.handle.net/10161/18009Published Version (Please cite this version)
10.1186/s12967-016-0903-zPublication Info
Zhou, Fei; Zhu, Meiling; Wang, Mengyun; Qiu, Lixin; Cheng, Lei; Jia, Ming; ... Wei,
Qingyi (2016). Genetic variants of DNA repair genes predict the survival of patients with esophageal
squamous cell cancer receiving platinum-based adjuvant chemotherapy. Journal of translational medicine, 14(1). pp. 154. 10.1186/s12967-016-0903-z. Retrieved from https://hdl.handle.net/10161/18009.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Qingyi Wei
Professor in Population Health Sciences
Qingyi Wei, MD, PhD, Professor in the Department of Medicine, is Associate Director
for Cancer Control and Population Sciences, Co-leader of CCPS and Co-leader of Epidemiology
and Population Genomics (Focus Area 1). He is a professor of Medicine and an internationally
recognized epidemiologist focused on the molecular and genetic epidemiology of head
and neck cancers, lung cancer, and melanoma. His research focuses on biomarkers and
genetic determinants for the DNA repair deficient phenotype and

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info